Obesity Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment
Stay ahead with the latest insights! Download DelveInsight's comprehensive Obesity Pipeline Report to explore emerging therapies, key Obesity Companies, and future Obesity treatment landscapes @ Obesity Pipeline Outlook Report
Key Takeaways from the Obesity Pipeline Report
In July 2025, Carmot Therapeutics Inc. announced a study to evaluate the efficacy and safety of CT-388 at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).
In July 2025, Innovent Biologics (Suzhou) Co. Ltd. conducted a study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study.
In July 2025, Zealand Pharma organized a study is to compare dose levels of petrelintide versus placebo with regards to effect on body weight, safety, and tolerability. Obesity is a chronic disease with a rapidly increasing prevalence associated with significant comorbidities. Petrelintide is a long-acting amylin analog in development for weight management.
In July 2025, Eli Lilly and Company conducted a study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.
In July 2025, Rhythm Pharmaceuticals Inc. organized a Phase 3 Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway.
DelveInsight's Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.
Discover how the Obesity treatment paradigm is evolving. Access DelveInsight's in-depth Obesity Pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies
Obesity Emerging Drugs
Survodutide: Zealand Pharma
Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity.
Ecnoglutide: Sciwind Biosciences
Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity.
CT-868: Carmot Therapeutics
CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868's effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity.
DD01: D&D Pharmatech
DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).
The Obesity pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.
Get a detailed analysis of the latest innovations in the Obesity pipeline. Explore DelveInsight's expert-driven report today! @ Obesity Unmet Needs
Obesity Companies
Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Obesity Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Obesity Therapies and key Obesity Developments @ Obesity Market Drivers and Barriers, and Future Perspectives
Scope of the Obesity Pipeline Report
Coverage- Global
Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.
Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Obesity drug development? Find out in DelveInsight's exclusive Obesity Pipeline Report—access it now! @ Obesity Emerging Drugs and Major Companies
Table of Contents
Introduction
Executive Summary
Obesity Overview
Obesity Pipeline Therapeutics
Obesity Therapeutic Assessment
Late Stage Products (Phase III)
Survodutide: Zealand Pharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
CT-868: Carmot Therapeutics
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
DD01: D&D Pharmatech
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Obesity Products
Obesity Key Companies
Obesity Key Products
Obesity Unmet Needs
Obesity Market Drivers
Obesity Market Barriers
Obesity Future Perspectives and Conclusion
Obesity Analyst Views
Obesity Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/obesity-pipeline-insight
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
2 hours ago
- CTV News
Anyone could forget a kid in a hot car, research shows
No parent thinks they'd forget their child in a hot car. But the tragic truth is that it can happen to anyone. Since 1998, about 1,024 children have died in hot cars—and more than half of them were left behind unknowingly by their caregiver, according to There have already been 14 hot car deaths among children in the U.S. in 2025 so far, with eight occurring in June alone, the organization says. But recent research highlights that the daily stresses parents face can make these memory lapses more likely. Forgetting a child isn't a negligence problem but a working memory problem, says David Diamond, PhD, a professor of psychology at the University of South Florida in Tampa. Diamond, a leading expert in cognitive neuroscience, has studied the role of memory in such tragedies. 'The most common response is that only bad or negligent parents forget kids in cars,' Diamond says. 'It's a matter of circumstances. It can happen to everyone.' During the summer, many families change their daily routines because of vacations or other reasons, and that disruption is a common factor in these tragic incidents, Diamond's research has found. Janette Fennell, founder and president of Kids and Car Safety, a group that tracks these incidents, says, 'The worst thing any parent or caregiver can ever do is to think that something like this could never happen to them or someone in their family.' These tragedies occur at an alarming rate, and they involve a range of circumstances. reports that deaths have spanned from 5-day-old babies to 14-year-olds. And deaths from heatstroke can happen any time of year, even as early as February and as late as November. Kids and Car Safety's heatstroke fact sheet highlights that caregivers involved in these incidents come from many walks of life. They include teachers, dentists, social workers, law enforcement officers, nurses, clergymen, military officers, and even a rocket scientist. These tragic cases can happen to anyone, regardless of their education or socioeconomic status. And it's not just a summertime problem. Even on days with mild temperatures, the heat inside a closed vehicle can reach dangerous levels within an hour, posing major health risks to small children or pets left inside, Consumer Reports' testing shows. When working memory fails Diamond says the problem involves two parts of a person's working memory: prospective and semantic. Prospective memory helps us remember to do something in the future, while semantic memory allows drivers to make the trip from work to home on autopilot, where they arrive without remembering clear details of how they got there. Prospective and semantic memories work together to help us make changes to our routines; these changes can include things such as 'drop off the baby at daycare' or 'stop for groceries on the way home.' When our working memory fails, such as when we're distracted or stressed, there can be catastrophic implications, Diamond says. He gave examples of situations where critical safety steps were overlooked, such as a surgeon leaving tools in a patient, a pilot not setting the wing flaps for landing, and caregivers forgetting that there's a baby in the car. 'The habit brain system is a great convenience that allows us to go into autopilot,' Diamond says. 'The beauty of it is that we don't have to remember every turn, but the problem is that it's actually guiding our behavior. When it guides our behavior, it suppresses the other part of the brain that is supposed to remind us of additional information.' 'We have to accept the fact that our brain multitasks. And as a part of that multitasking, the awareness of a child can be lost,' Diamond says. 'We have to accept that the human memory is flawed. That includes when loving, attentive parents lose awareness of their children when they are in a car.' Diamond has studied many heatstroke cases and points to common factors: stress, sleep deprivation, and change in routine. Many times when a child died in this situation, there was a change in the day's routine, Diamond says. For example, a parent who wouldn't usually be responsible for day-care drop-off may have had the task that day. Because our brains recognize a pattern for the day, this person would drive to work as usual, even though the baby was along for the ride. And unless there was an external cue, such as seeing the diaper bag or hearing the baby, the parent's brain would continue on autopilot and could even create a false memory that the child is safely at daycare, Diamond found. Sleep deprivation and stress can also increase the potential for a working-memory failure. Conflicts between semantic and prospective memory are typical, Diamond says. His research has found that they happen to everyone—not just parents and caregivers—on almost a daily basis. The added stress, distraction, and sleep deprivation that parents often face can contribute to tragic situations. What you can do to prevent a hot car tragedy The first step is for parents and caregivers to understand that human memory is faulty and that these memory failures can happen to anyone. The key to avoiding such incidents is to use strategies aimed at overcoming memory lapses. 'The strategies need to be child-specific,' Diamond says. 'When you have a child in the car, do something unique.' Here are six tips from the expert team that tests car seats for CR. Create safeguards. Set up an agreement with child-care providers where you promise to notify them if your child is going to be late or absent. In return, they pledge to notify you if your child doesn't arrive at the usual drop-off time. Set up an agreement with child-care providers where you promise to notify them if your child is going to be late or absent. In return, they pledge to notify you if your child doesn't arrive at the usual drop-off time. Set reminders on your phone to check with your spouse or partner to make sure they have dropped the child off. to check with your spouse or partner to make sure they have dropped the child off. Always keep vehicles locked and keys out of reach from little hands. and keys out of reach from little hands. Create visual reminders. Place the child's diaper bag, jacket, or hat in the front passenger seat. Place the child's diaper bag, jacket, or hat in the front passenger seat. Force yourself to go to the back seat. Keep your backpack, lunch box, or briefcase there every day. Keep your backpack, lunch box, or briefcase there every day. Never leave a child unattended in a vehicle for any length of time, regardless of the outside temperature. Vehicles can quickly heat up to potentially fatal levels on even mild-temperature days. 'Education is very important, but education alone won't end these tragedies,' says Fennell at Kids and Cars Safety. 'It's going to take education along with technology to help our imperfect brains.' You can also invest in a vehicle or child car seat with integrated reminder technology. Consumer Reports' experts have evaluated these technologies and found that integrated systems that default to On, rather than needing to be activated by the driver, are the most beneficial. (The concern is that most parents don't think a hot car tragedy could happen to them and therefore might not turn on a protective feature.) 'When my college-aged son was an infant, this almost happened to us,' says Jennifer Stockburger, director of operations at CR's Auto Test Center. 'My husband was responsible for dropping our son at daycare one day, which was not his normal routine. He drove far past the daycare, and only when our son made some noise did he realize his mistake. Even if you can't imagine making such an error, I encourage parents to use the tips we provide to safeguard their children.' By Emily A. Thomas, PhD, Consumer Reports associate director, auto safety
Globe and Mail
8 hours ago
- Globe and Mail
Luxury Aesthetics Reimagined: Beauty Factory LV Launches Cutting-Edge Morpheus8 RF Microneedling and Signature Sculpting Treatments
Las Vegas, Nevada--(Newsfile Corp. - July 18, 2025) - Beauty Factory LV, the premier destination for high-end aesthetics in Las Vegas, has officially expanded its service offerings with the launch of Morpheus8 Advanced RF Microneedling, along with a curated suite of bespoke injectables and sculpting treatments. This new chapter signals a commitment to providing next-generation, non-surgical solutions for clients seeking luxury results with minimal downtime. Figure 1: Beauty Factory To view an enhanced version of this graphic, please visit: A Revolution in Skin Rejuvenation At the forefront of the launch is the Morpheus8 Advanced RF Microneedling treatment—a breakthrough technology that blends deep microneedling with targeted radiofrequency energy. This premium, minimally invasive service is designed to lift, tighten, and rejuvenate the skin, making it ideal for contouring the jawline, smoothing fine lines, and revitalizing aging or dull complexions. "This is not your average facial," said Maise Pastrano, a representative for Beauty Factory LV. "With Morpheus8, our clients can achieve sculpted, youthful results with clinical precision—without going under the knife." Injectable Artistry with Natural Elegance Complementing the Morpheus8 treatment, Beauty Factory LV now offers precision dermal fillers focused on facial contouring—particularly the chin and lips. These bespoke injectables are tailored to each client's anatomy, enhancing facial harmony while maintaining a natural look. Recent client transformations—highlighted across the brand's Instagram—showcase the subtle yet striking outcomes from expertly placed fillers, further solidifying Beauty Factory LV's reputation as a go-to for natural refinement. Botox Beyond Beauty: TMJ & Jaw Slimming Treatments In addition to cosmetic enhancements, Beauty Factory LV is also offering Botox for TMJ relief and jaw slimming. This innovative, non-invasive treatment helps reduce jaw tension while subtly refining the lower face—merging wellness and aesthetics in a seamless experience. About Beauty Factory LV Beauty Factory LV is a boutique medical aesthetics studio based in Las Vegas, specializing in advanced, non-surgical cosmetic treatments that blend science, luxury, and artistry. Known for delivering elite-level care in a serene, client-first environment, the studio continues to raise the bar in modern beauty.
Globe and Mail
13 hours ago
- Globe and Mail
1st Choice Personal Care Continues Dedicated Service, Offering Premier Senior Home Care in Indianapolis
1st Choice Personal Care reaffirms its commitment to delivering high-quality, compassionate senior home care in Indianapolis. Led by Latorious Wilkes, the agency empowers seniors to age in place with dignity and independence through personalized, non-medical support like personal care, companionship, and household help. Families gain peace of mind knowing their loved ones are cared for with empathy and respect. Learn more at Indianapolis, IN - 1st Choice Personal Care, a leading provider of non-medical home care, today announced its ongoing commitment to serving the families of Indianapolis. The agency continues to provide exceptional senior home care in Indianapolis, ensuring that the elderly can live with dignity and maintain their lifestyle in the comfort and familiarity of their own homes. This focused effort addresses the growing need for reliable and compassionate caregivers in the community. Founded on the principles of client-centered care, dignity, and respect, 1st Choice Personal Care has established itself as a trusted partner for families navigating the challenges of aging. The agency, under the leadership of Latorious Wilkes, offers a comprehensive suite of services, including personal assistance with daily activities, meal preparation, medication reminders, light housekeeping, and companion care. The team is committed to delivering high-quality support that enriches the lives of its clients. One of the most significant benefits of the services provided by 1st Choice Personal Care is the ability for seniors to age in place. Remaining at home, surrounded by cherished memories and familiar comforts, has been shown to significantly improve emotional well-being and reduce the stress associated with relocating to a facility. This approach empowers seniors by allowing them to retain a sense of independence and control over their daily routines, fostering confidence and a higher quality of life. Furthermore, the agency's model provides invaluable peace of mind for families. Knowing a professional and compassionate caregiver is tending to a loved one alleviates the pressures on family members, allowing them to focus on strengthening personal connections rather than managing caregiving tasks. The personalized nature of in-home senior care in Indianapolis means that each client receives a care plan tailored to their specific needs, ensuring they get the dedicated attention and companionship essential for both physical and mental health. "Our mission has always been to provide the kind of care that we would want for our family members," said Latorious Wilkes, owner of 1st Choice Personal Care. "We believe everyone deserves to live with dignity and independence, and for many seniors, that means staying in their own home. We are steadfast in our commitment to the Indianapolis community, providing a reliable and compassionate choice for families seeking support." As the demand for senior care continues to grow, 1st Choice Personal Care remains a pillar of support in the Indianapolis area. The agency's unwavering dedication ensures that local families will continue to have access to high-quality, personalized, and respectful care for their loved ones. For more information about 1st Choice Personal Care and their senior home care in Indianapolis, IN, please visit their website at About 1st Choice Personal Care: 1st Choice Personal Care, LLC is a licensed personal service agency based in Indianapolis, IN, offering a range of non-medical home care services. The agency is dedicated to providing client-centered care with compassion, dignity, and respect, assisting elderly and disabled clients with the activities of daily living to help them maintain their independence at home. Media Contact Company Name: 1st Choice Personal Care Contact Person: Latorious Wilkes Email: Send Email Phone: +1 317-936-1946 Address: 6801 Lake Plaza Dr Suite A-112 City: Indianapolis State: IN Country: United States Website:
